Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM


Phase I Trial of SAR650984 and Phase I/II Trial of Daratumumab for Patients with Relapsed/Refractory MM
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Martin TG et al. A Phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Proc ASH 2014;Abstract 83.

Plesner T et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Proc ASH 2014;Abstract 84.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.